Brilintas phase 3 THEMIS trial met primary endpoint in patients with established coronary artery disease and type2 diabetes

Brilinta’s phase 3 THEMIS trial met primary endpoint in patients with established coronary artery disease and type-2 diabetes

02:53 EST 26 Feb 2019 | Pharmaceutical Business Review

THEMIS was conducted in over 19,000 patients with coronary artery disease (CAD) and type-2 diabetes (T2D) with no prior heart attack (myocardial infarction, MI) or stroke. Preliminary safety

More From BioPortfolio on "Brilinta’s phase 3 THEMIS trial met primary endpoint in patients with established coronary artery disease and type-2 diabetes"